Candel Therapeutics CADL
NASDAQ CADL
$9.42 +0.07 (+0.75%)
As of: Nov 11, 2026 · 2:06 PM EST

Candel Therapeutics (CADL) Non-Current Deferred Revenue (2020 - 2026)

Updated

Candel Therapeutics (CADL) posted Non-Current Deferred Revenue of $45,000 for Q2 2026.

Analysis

Candel Therapeutics (CADL) Non-Current Deferred Revenue (2020 - 2026) Analysis & Trends

At the end of FY2025, Candel Therapeutics' Non-Current Deferred Revenue came in at $89,000.

  • Annual Non-Current Deferred Revenue shows a five-year compound annual growth rate of -6.6% (FY2020 to FY2025).
  • In prior years, Candel Therapeutics' Non-Current Deferred Revenue was $144,000 in FY2022.
  • The Q2 2026 figure stands as the lowest quarterly Non-Current Deferred Revenue since Q3 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Candel Therapeutics 711.71 Mn 108.61 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 45,000.00
Mar 31, 2026 67,000.00
Dec 31, 2025 89,000.00
Sep 30, 2023 108,000.00
Jun 30, 2023 120,000.00
Mar 31, 2023 132,000.00
Dec 31, 2022 144,000.00
Sep 30, 2021 31,000.00
Jun 30, 2021 63,000.00
Dec 31, 2020 125,000.00
API Access

Candel Therapeutics Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=CADL&period=max&api_key=YOUR_API_KEY